Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 18/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20766350 | 0.91 | HTR2A (0.51) | HTR2ASLC6A2SLC6A4KDM4EALDH1A1 | |
| SCHEMBL20766247 | 0.91 | HTR2A (0.62) | HTR2ASLC6A2SLC6A4KDM4EALDH1A1 | |
| SCHEMBL20766381 | 0.90 | HTR2A (0.63) | HTR2ASLC6A2SLC6A4 | |
| SCHEMBL20766347 | 0.81 | ALDH1A1 (0.52) | HTR2ASLC6A2SLC6A4KDM4EALDH1A1 | |
| SCHEMBL20766880 | 0.81 | HTR2A (0.65) | HTR2ASLC6A2SLC6A4 | |
| SCHEMBL20766382 | 0.81 | HTR2A (0.55) | HTR2ASLC6A2SLC6A4KDM4EALDH1A1 | |
| SCHEMBL20778732 | 0.80 | HTR2A (0.62) | HTR2ASLC6A2SLC6A4 | |
| SCHEMBL20766478 | 0.80 | HTR2A (0.64) | HTR2A | |
| SCHEMBL20766399 | 0.80 | HTR2A (0.66) | HTR2A | |
| SCHEMBL20766412 | 0.79 | HTR2A (0.50) | HTR2ASLC6A2SLC6A4KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3672954-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | Acadia Pharmaceuticals Inc. (US) | 2020-07-01 | — | — | EP | disclosed |
| WO-2019040107-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARMACEUTICALS INC. (US) | 2019-02-28 | — | — | WO | disclosed |